1. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents
- Author
-
Byonanebye D. M., Polizzotto M. N., Begovac J., Grabmeier-Pfistershammer K., Abela I., Castagna A., de Wit S., Mussini C., Vehreschild J. J., d'Arminio Monforte A., Wit F. W. N. M., Pradier C., Chkhartishvili N., Sonnerborg A., Hoy J., Lundgren J., Neesgaard B., Bansi-Matharu L., Greenberg L., Llibre J. M., Vannappagari V., Gallant J., Necsoi C., Cichon P., Reiss P., Aho I., Tsertsvadze T., Mennozzi M., Rauch A., Muccini C., Law M., Mocroft A., Ryom L., Petoumenos K., Hillebregt M., Rose N., Zangerle R., Appoyer H., Delforge M., Wandeler G., Stephan C., Bucht M., Chokoshvili O., Rodano A., Tavelli A., Fanti I., Borghi V., Fontas E., Dollet K., Caissotti C., Casabona J., Miro J. M., Smith C., Lampe F., Johnson M., Burns F., Chaloner C., Lazzarin A., Poli A., Falconer K., Svedhem V., Gunthard H., Ledergerber B., Bucher H., Scherrer A., Wasmuth J. C., Rockstroh J., Fatkenheuer G., Stecher M., Schulze N., Franke B., Rooney J., Rogatto F., Garges H., Kowalska J., Raben D., Peters L., Anne A. V., Dedes N., Williams E. D., Bruguera A., Haubrich R., Svedhem-Johansson V., Bloch M., Braun D., Calmy A., Schuttfort G., Youle M., Zona S., Antinori A., Bolokadze N., Schwarze-Zander C., Duvivier C., Dragovic G., Radoi R., Oprea C., Vasylyev M., Matulionyte R., Mulabdic V., Marchetti G., Kuzovatova E., Coppola N., Martini S., Harxhi A., Waehre T., Pharris A., Vassilenko A., Bogner J., Maagaard A., Jablonowska E., Elbirt D., Marrone G., Leen C., Wyen C., Kundro M., Thorpe D., Volny-Anne A., Mendao L., Larsen J. F., Jakobsen M. L., Bruun T., Bojesen A., Hansen E. V., Elsing T. W., Kristensen D., Thomsen S., Weide T., Pelchen-Matthews A., Byonanebye, D. M., Polizzotto, M. N., Begovac, J., Grabmeier-Pfistershammer, K., Abela, I., Castagna, A., de Wit, S., Mussini, C., Vehreschild, J. J., d'Arminio Monforte, A., Wit, F. W. N. M., Pradier, C., Chkhartishvili, N., Sonnerborg, A., Hoy, J., Lundgren, J., Neesgaard, B., Bansi-Matharu, L., Greenberg, L., Llibre, J. M., Vannappagari, V., Gallant, J., Necsoi, C., Cichon, P., Reiss, P., Aho, I., Tsertsvadze, T., Mennozzi, M., Rauch, A., Muccini, C., Law, M., Mocroft, A., Ryom, L., Petoumenos, K., Hillebregt, M., Rose, N., Zangerle, R., Appoyer, H., Delforge, M., Wandeler, G., Stephan, C., Bucht, M., Chokoshvili, O., Rodano, A., Tavelli, A., Fanti, I., Borghi, V., Fontas, E., Dollet, K., Caissotti, C., Casabona, J., Miro, J. M., Smith, C., Lampe, F., Johnson, M., Burns, F., Chaloner, C., Lazzarin, A., Poli, A., Falconer, K., Svedhem, V., Gunthard, H., Ledergerber, B., Bucher, H., Scherrer, A., Wasmuth, J. C., Rockstroh, J., Fatkenheuer, G., Stecher, M., Schulze, N., Franke, B., Rooney, J., Rogatto, F., Garges, H., Kowalska, J., Raben, D., Peters, L., Anne, A. V., Dedes, N., Williams, E. D., Bruguera, A., Haubrich, R., Svedhem-Johansson, V., Bloch, M., Braun, D., Calmy, A., Schuttfort, G., Youle, M., Zona, S., Antinori, A., Bolokadze, N., Schwarze-Zander, C., Duvivier, C., Dragovic, G., Radoi, R., Oprea, C., Vasylyev, M., Matulionyte, R., Mulabdic, V., Marchetti, G., Kuzovatova, E., Coppola, N., Martini, S., Harxhi, A., Waehre, T., Pharris, A., Vassilenko, A., Bogner, J., Maagaard, A., Jablonowska, E., Elbirt, D., Marrone, G., Leen, C., Wyen, C., Kundro, M., Thorpe, D., Volny-Anne, A., Mendao, L., Larsen, J. F., Jakobsen, M. L., Bruun, T., Bojesen, A., Hansen, E. V., Elsing, T. W., Kristensen, D., Thomsen, S., Weide, T., and Pelchen-Matthews, A.
- Subjects
0301 basic medicine ,Anti-HIV Agents ,Immunology ,Integrase inhibitor ,Blood lipids ,HIV Infections ,Tenofovir alafenamide ,03 medical and health sciences ,0302 clinical medicine ,ANTIRETROVIRAL AGENTS ,medicine ,Humans ,Immunology and Allergy ,Protease inhibitor (pharmacology) ,Prospective Studies ,HIV Integrase Inhibitors ,030212 general & internal medicine ,Myocardial infarction ,Dyslipidemias ,business.industry ,Incidence ,Incidence (epidemiology) ,dyslipidemia ,HIV ,medicine.disease ,Virology ,antiretroviral agents ,integrase inhibitors ,030104 developmental biology ,Infectious Diseases ,Anti-Retroviral Agents ,Reverse Transcriptase Inhibitors ,business ,Dyslipidemia - Abstract
Objective: To compare the incidence of dyslipidemia in people with HIV receiving integrase inhibitors (INSTI) versus boosted protease inhibitors (PI/b) and nonnucleoside reverse transcriptase inhibitors (NNRTI) within RESPOND consortium of prospective cohorts. Methods: Participants were eligible if they were at least 18 years, without dyslipidemia and initiated or switched to a three-drug antiretroviral therapy (ART)-regimen consisting of either INSTI, NNRTI, or PI/b for the first time, between 1 January 2012 and 31 December 2018. Dyslipidemia was defined as random total cholesterol more than 240 mg/dl, HDL less than 35 mg/dl, triglyceride more than 200 mg/dl, or initiation of lipid-lowering therapy. Poisson regression was used to determine the adjusted incidence rate ratios. Follow-up was censored after 3 years or upon ART-regimen discontinuation or last lipid measurement or 31 December 2019, whichever occurred first. Results: Overall, 4577 people with HIV were eligible (INSTI = 66.9%, PI/b = 12.5%, and NNRTI = 20.6%), 1938 (42.3%) of whom were ART-naive. During 1.7 (interquartile range, 0.6 - 3.0) median years of follow-up, 1460 participants developed dyslipidemia [incidence rate: 191.6 per 1000 person-years, 95% confidence interval (CI) 182.0 - 201.7]. Participants taking INSTI had a lower incidence of dyslipidemia compared with those on PI/b (adjusted incidence rate ratio 0.71; CI 0.59 - 0.85), but higher rate compared with those on NNRTI (1.35; CI 1.15 - 1.58). Compared with dolutegravir, the incidence of dyslipidemia was higher with elvitegravir/cobicistat (1.20; CI 1.00 - 1.43) and raltegravir (1.24; CI 1.02 - 1.51), but lower with rilpivirine (0.77; CI 0.63 - 0.94). Conclusion: In this large consortium of heterogeneous cohorts, dyslipidemia was less common with INSTI than with PI/b. Compared with dolutegravir, dyslipidemia was more common with elvitegravir/cobicistat and raltegravir, but less common with rilpivirine.
- Published
- 2021
- Full Text
- View/download PDF